Summary of Key Points
Merck's first oral PCSK9 inhibitor, Lipfendra, has been approved by the FDA. This once-daily pill demonstrates similar lipid-lowering effects (a nearly 60% reduction in bad cholesterol) to injectable PCSK9 therapies. However, there is significant disagreement in the market regarding its prospects: Optimists believe that the oral formulation could address the compliance issues associated with injections (patients' fear of needles and doctors' reluctance to prescribe them), potentially opening up a billion-dollar market. More cautious observers, including Novartis and Merck itself, argue that the format iteration alone is not decisive; the real winners will be determined by evidence of cardiovascular outcomes (whether it can truly reduce myocardial infarctions/strokes), guideline recommendations, and payment policies. The launch of Lipfendra coincides with updates to medical guidelines, breaking the previous paradigm where PCSK9 was only considered a "high-end, later-line treatment," thereby changing the underlying logic of lipid-lowering therapy and intensifying competition in this field.
Detailed Analysis
1. The Battle of Formulations: Oral vs. Injection – Which Is More Convenient?
Over the past decade, injectable PCSK9 inhibitors (such as alirocumab) have been highly effective in lowering cholesterol levels. However, they faced a major challenge: 95% of primary care physicians had never prescribed them due to patients' fear of injections and the inconvenience of regular dosing (e.g., every two weeks/month). The introduction of the oral Lipfendra theoretically eliminates this barrier, allowing patients to take the medication like a common blood pressure pill without the need for hospital visits. However, market reactions have been mixed:
- Novartis remains unfazed: Its Leqvio is an injectable PCSK9 therapy administered twice a year using siRNA technology. The CEO stated, "With oral administration once daily, our twice-yearly dosing is even more convenient." Leqvio sold $932 million in the first half of this year, showing a 64% increase in sales, and its share of U.S. Medicare Part B coverage (reimbursement for medications administered in doctors' offices) has reached 23.3%. Demand in China has also doubled since the drug was included in the healthcare system. This indicates that the compliance requirements for the two formulations differ: Oral medications rely on patients' self-discipline, while Leqvio is better suited for high-risk patients with memory issues or advanced age who may have difficulty remembering to take injections.
- Analysts' Views Diverge: Some predict that Lipfendra's sales will be negligible by 2026, and Merck itself acknowledges that market adoption will be slow (it will take time to educate doctors and patients). Others estimate that Lipfendra could achieve sales of $476 million by 2027.
2. Cardiovascular Outcomes: Lowering Cholesterol Is Not Enough – Hard Endpoints Are the Real Test
The ultimate goal of lipid-lowering drugs is not just to reduce bad cholesterol levels but to prevent life-threatening events such as myocardial infarctions, strokes, and deaths (known as "cardiovascular hard endpoints"). Lipfendra has only proven its ability to lower cholesterol levels; large-scale trials are still needed to demonstrate its effectiveness in reducing these outcomes.
Why is this crucial?
- Previous injectable PCSK9 inhibitors, like alirocumab, have met the criteria for being recommended by guidelines and covered by insurance, making them doctors' first choice.
- Drugs without hard endpoint evidence, even if effective, may be considered secondary options. For example, Novartis' Leqvio is only designated as a substitute for injectable monoclonal antibodies in guidelines.
- Both Merck and Novartis are conducting additional trials to gather data on cardiovascular outcomes. Lipfendra involves 14,500 participants, with results expected in 2029; similar trials for Leqvio are also underway, with data expected by 2027. Only by providing evidence of hard endpoints can Lipfendra transition from a "new drug" to a standard treatment.
3. Shifting Guidelines: From "Later-Line Therapy" to "Early-Stage Standard Treatment"
Previously, PCSK9 inhibitors were considered high-end treatments, prescribed only by cardiologists or lipid specialists for patients with very severe conditions (those who had already experienced a myocardial infarction). This is changing:
- Guideline Updates: The 2026 U.S. lipid guidelines have lowered the cholesterol target for high-risk patients to below 55 mg/dL and recommend PCSK9 alongside ezetimibe as part of early combined therapy, no longer treating them as a last-resort option.
- Oral Formulations Facilitate Expansion: In the past, prescribing PCSK9 required a switch from oral to injectable medications, which was a psychological barrier for doctors. Now, oral formulations enable general practitioners and endocrinologists to prescribe it, potentially reaching a broader patient base.
However, widespread adoption depends on price and reimbursement policies. If Lipfendra remains expensive, it will only solve the convenience issue; if prices are reduced and insurance covers the cost, more patients who do not meet cholesterol targets will be able to use it.
4. Intense Competition in the Field: Diverse Technological Approaches
The PCSK9 competition has moved from verifying the effectiveness of therapeutic targets to competing for patient loyalty. Current approaches include:
- Injectable Monoclonal Antibodies (Alirocumab, Alirocumab): These have proven efficacy but require frequent injections.
- siRNA (Leqvio): Convenient once every six months but lack hard endpoint evidence.
- Oral Macrocycles (Lipfendra): Once-daily administration but also without hard endpoint evidence.
- Other research directions include fusion proteins and small molecules.
The situation is similar in China, where monoclonal antibodies like toricizumab and recalcitumab have been included in the healthcare system, with oral macrocycle therapies also in development. The winner will be the one that satisfies all three parties:
- Patients: Desire for convenience and minimal side effects.
- Doctors: Ease of prescription due to guideline recommendations and evidence of efficacy.
- Payors: Willingness to cover the cost based on reasonable pricing and clinical value.
The approval of Lipfendra is just the beginning; the real competition is yet to unfold.
Conclusion
Lipfendra adds momentum to the lipid-lowering therapy market, but its success as a game-changer depends on more than just its oral format. Ultimately, it will need to demonstrate efficacy in reducing cardiovascular outcomes, gain guideline recognition, and be affordable. It must also compete effectively against other formulations (such as Leqvio, which requires twice-yearly dosing). For patients, this will mean more convenient and effective options for managing cholesterol levels. For pharmaceutical companies, the battle is just beginning.